Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain
Abraldes, M.J. (Complexo Hospitalario Universitario de Santiago)
Calvo, P. (Hospital Universitario Miguel Servet (Saragossa))
Gámez Lechuga, María (Institut de Recerca Sant Pau)
Merino, M. (Weber)
Martín Lorenzo, T. (Weber)
Maravilla Herrera, Paulina (Weber)
Gil Jiménez, B. (Roche Farma)
Ruiz-Moreno, J.M. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Universitat Autònoma de Barcelona

Date:	2024
Abstract:	Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that causes severe and irreversible vision loss. The disease can therefore have a significant impact on the life of patients' and their families. The aim of this study was to evaluate the socio-economic burden of nAMD in Spain. The annual cost per patient with nAMD was estimated for the first, second, and third year (or beyond) of treatment since diagnosis. Several cost categories were considered including direct healthcare costs (DHC), direct non-healthcare costs (DNHC), labor productivity losses (LPL), and intangible costs (IC) related to loss of quality of life. The average annual cost per patient was estimated by assigning a unit price or financial proxy to the resources consumed per patient. Reference year of costs was 2021. The mean annual cost of nAMD was estimated at €17,265, €15,403, and €14,465 per patient in the first, second, and third year of treatment after diagnosis. There was an additional one-off cost of €744 associated with the diagnosis of nAMD. DHC accounted for most of the total annual cost per patient independent of the year of treatment since diagnosis (48% in year 1; 42% in year 2; 39% in year 3). Similarly, DNHC had an important contribution to the total costs (32% in year 1; 35% in year 2; 37% in year 3), followed by IC (20% in year 1; 23% in year 2; 24% in year 3), while the contribution of patients' LPL was minimal. This study estimated a high economic burden associated with nAMD for patients and their families, the healthcare system, and society at large. There is a need to improve the management of these patients to reduce the impact of nAMD disease progression.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Burden of disease ; Healthcare costs ; Non-healthcare costs ; Productivity losses ; Quality of life ; Resource consumption ; Namd
Published in:	Ophthalmology and Therapy, Vol. 13 Núm. 7 (july 2024) , p. 1925-1935, ISSN 2193-6528

DOI: 10.1007/s40123-024-00960-9
PMID: 38771461

11 p, 615.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles